

Research Article

Clinical Effects and Safety of Auricular Acupressure as an Adjunct Therapy on Postoperative Pain among Patients with Hip Fracture: A Meta-Analysis

Pin Li 🝺, Hongyun Chen 🝺, Xiuzhen Fu 🝺, Haili Zhou 🝺, and Fan Lai 🝺

Department of Orthopedic, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China

Correspondence should be addressed to Hongyun Chen; chenhongyun0210@126.com

Received 21 October 2022; Revised 30 January 2023; Accepted 6 April 2023; Published 24 April 2023

Academic Editor: Lidiane L. Florencio

Copyright © 2023 Pin Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objectives. To evaluate the short-term outcome of treatment by auricular acupressure (AA) on postoperative pain among hip fracture (HF) patients. *Methods.* A systematic search for randomized controlled trials on this topic was conducted through May 2022 by searching multiple English and Chinese databases. The methodological quality of the included trails was assessed by the Cochrane Handbook tool, and relevant data were extracted and statistically analyzed by RevMan 5.4.1 software. The quality of the evidence supporting each outcome was evaluated by GRADEpro GDT. *Results.* Fourteen trials with a total of 1390 participants were included in this study. Compared with conventional treatment (CT) alone, the combination of AA and CT had a significantly greater effect on the visual analog scale at 12 h (MD –0.53, 95% CI –0.77 to –0.30), 24 h (MD –0.59, 95% CI –0.92 to –0.25), 36 h (MD –0.07, 95% CI –0.13 to –0.02), 48 h (MD –0.52, 95% CI –0.97 to –0.08), and 72 h (MD –0.72, 95% CI –1.02 to –0.42), amount of analgesics used (MD –12.35, 95% CI –14.21 to –10.48), Harris Hip Score (MD 6.58, 95% CI 3.60 to 9.56), effective rate (OR 6.37, 95% CI 2.68 to 15.15), and adverse events (OR 0.35, 95% CI 0.17 to 0.71). *Conclusions*. Compared with CT alone, the combination of AA and CRT had a significantly greater effect on postoperative pain in HF patients. However, trails with a rigorous methodology, including standard protocols for AA and multiethnic subjects, are still needed.

1. Introduction

As the aging process of the population continues to accelerate, the proportion of the elderly (>60 years) will continue to increase [1]. It is estimated that by 2050, the proportion of the elderly population will reach 21.1% worldwide [2, 3]. Hip fracture is a common type of fracture in the elderly and ranks among the top 10 of disability [4]. It is estimated that the absolute number of hip fractures is expected to increase from 1.6 million in 2000 to 6.3 million by the year 2050 [5]. Hip fracture (HF) has become a worldwide health problem, it is estimated that the annual cost of HF treatment has increased from approximately 10.3 to 15.2 billion dollars in 1990 to 17 billion in 2002 [6].

Timely surgery for hip fractures remains the mainstay of treatment, including internal fixation, total hip arthroplasty, and hemiarthroplasty [7]. Many official clinical societies recommend postoperative multi-modal analgesia [8] because elderly patients with inadequate postoperative pain control are reluctant to mobilize, thus increasing the potential risk of complications and slowing recovery [9]. Adequate analgesia is of great significance. Current strategies for pain management include oral and parenteral systemic analgesia, and systematic administration of opioids remains the most commonly used analgesia protocol [10]. While opioids are effective in relieving static pain, they may not be sufficient for dynamic pain [11]. Furthermore, the use of opioids may bring side effects, such as delirium, drowsiness, and even respiratory depression, which may affect the prognosis of patients [12]. Thus, to lower the risk of adverse events and also guarantee treatment efficacy, complementary and alternative therapies have been investigated and compared.

Acupuncture is a traditional nonpharmacological treatment in China and has been widely recognized worldwide [13]. Available evidence suggests that acupuncture is effective for pain relief, thus the World Health Organization recommends the use of acupuncture for a variety of pains, including postoperative pain [13]. As an important component of acupuncture [14], auricular acupressure (AA) has also been deemed effective for pain management by the National Institutes of Health [15]. A literature search yielded many published clinical randomized controlled trials (RCTs) of AA for postoperative pain among HF patients. Consequently, the aim of this study was to evaluate the short-term outcome of treatment by AA on postoperative pain among HF patients by conducting a systematic literature review and meta-analysis of RCTs.

2. Methods

The protocol of this study was registered in PROSPERO (https://www.crd.york.ac.uk/prospero). This work was performed following criteria in the Cochrane Handbook [16] and reported in line with preferred reporting items for systematic reviews and meta-analyses (PRISMA) [17].

2.1. Search Strategy. Eight databases (Pubmed, EMBASE, Cochrane Library, Web of Science, China National Knowledge, and Wan Fang Database, China National Knowledge Infrastructure, Chongqing VIP, and Sino-Med) were searched on May 18, 2022, using the following keywords: auricular acupressure, hip fracture, randomized clinical trials. The detailed search strategy for PubMed is given in supplementary file A.

2.2. Criteria for Considering Studies. Included criteria were as follows: (i) type of study: published randomized controlled trial (RCT) in English and Chinese; (ii) intervention: AA with conventional treatment (CT); (iii) comparison: CT; (iv) population: diagnosed as having a hip fracture confirmed by imaging, regardless of race, sex, or age; and (v) outcome: pain intensity (visual analog scale (VAS)) at 12, 24, 36, 48, and 72 h after surgery the amount of analgesics used, the Harris Hip Score (HPS), the effective rate (ER), and adverse events (AE). In general, ER is defined by the formula: ER = ("total number of patients" – "number of patients without response")/total number of patients; "no response" is defined as no significant change in VAS score after treatment. Trails of AA with more than one Traditional Chinese medicine treatment technique as an intervention were also excluded.

2.3. Study Identification. Search results were imported into Endnote and duplicates were removed. Two research studies independently screen the titles and abstracts of the retrieved articles, evaluate the potential full texts, and determine the

eligibility of the reviews. Any discrepancies were solved by introducing a third researcher for judgment.

Data were extracted by two independent research studies using a predefined form, including: first author, year, country, simple size, characteristics of patients, course of disease, treatment protocol, outcome indicators, and consequences of and outcomes. Resolve any discrepancies through consultation.

2.4. Quality Assessment. Two research studies independently assessed the risk of bias by using the Cochrane Collaboration tool [18]. Each trail could be judged to be at "low," "high," or "unclear" risk of bias according to the domains of random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete dataset, selective reporting, and other bias. If more than half of the domains were assessed as having a low risk of bias, the trial was assessed as having a low overall risk of bias; if more than half of the domains were assessed as having a low overall risk of bias; the trial was assessed as having a low overall risk of bias; the trial was assessed as having a high risk of bias or an unclear risk of bias, the trial was assessed as having a high overall risk of bias. Resolve any discrepancies through consultation.

2.5. Data Synthesis. The odds ratio (OR) with 95% of CIs for dichotomous outcomes and the mean difference (MD) for continuous variables. The heterogeneity of the studies was assessed using the I^2 . If $I^2 < 50\%$, there was no significant heterogeneity among studies, and a fixed effect model was used to analyze the data. If $I^2 \ge 50\%$ of the heterogeneity among the studies was significant and a random effect model was used to provide the evaluations of the intervention. Subgroup analyses were determined by whether the obtained data were sufficient. A funnel plot was used to assess publication bias.

2.6. Level of Evidence. Two research studies independently assessed the certainty of evidence for each outcome using a grading of recommendations assessment, development, and evaluation (GRADE) system [19]. The GRADE guide-line consists of seven domains, namely, risk of bias, in-consistency, indirectness, imprecision, and publication bias. The certainty of the evidence was rated as high, moderate, low, and very low. The summary of findings table was created by the GRADEpro GDT (https://gradepro.org/). Resolve any discrepancies through consultation.

3. Results

3.1. Literature Screening. Literature screening flowchart is shown in Figure 1. A total of 460 trails were identified. After removing duplications, the titles and abstracts of 267 trails were further evaluated. Next, the full texts of the remaining 21 records were assessed, and 14 trails were finalized for inclusion in our meta-analysis [20–33].

3.2. General Characteristics. Characteristics of the included trails are presented in Table 1. 1390 participants were included from the 14 RCTs, which were published between 2012 and



FIGURE 1: Literature screening flowchart.

TABLE 1: Characteristics of the included trails.

<u>6</u> (]	c: 1 ·	А	ge	Intervent	tion		0.4
Study	Simple size	Ι	С	Ι	С	Inerapy duration	Outcomes
Li et al. [20]	35/35	68.94 ± 5.66	69.67 ± 5.52	AA + CT	СТ	3~5 t/d, 3 d	VAS, HHS, AAS
Xu and Li [21]	38/38	66.80 ± 3.73	66.88 ± 3.79	AA + CT	CT	3~5 t/d, 2 d	VAS, AAS
Sun [22]	48/48	N/A	N/A	AA + CT	CT	3~5 t/d, 3 d	ER
Wu and Wang [23]	35/33	39.5 ± 7.1	41.3 ± 7.2	AA + CT	CT	4~6 t/d, 3 d	VAS, AAS, AE
Wang et al. [24]	40/40	N/A	N/A	AA + CT	CT	3~5 t/d	HHS, AE
Yang [25]	60/60	54.6 ± 8.1	53.4 ± 8.3	AA + CT	CT	3~4 t/d	VAS, ER
Chen [26]	30/30	73.56 ± 7.09	73.48 ± 6.82	AA + CT	CT	4 t/d	VAS
Lv [27]	49/49	59.8 ± 8.6	59.5 ± 8.7	AA + CT	CT	3~5 t/d, 3 d	VAS
Zhu [28]	235/183	59.84 ± 6.13	60.19 ± 5.74	AA + CT	CT	4 t/d	VAS, HHS, AAS, AE
Shen and Zhou [29]	40/40	N/A	N/A	AA + CT	CT	3~5 t/d, 3 d	VAS, HHS
Tian et al. [30]	36/36	N/A	N/A	AA + CT	CT	3~5 t/d, 3 d	VAS
Xu [31]	19/19	60.74 ± 8.76	59.32 ± 7.68	AA + CT	CT	3~5 t/d, 3 d	VAS, AE
Wang et al. [32]	30/30	60.93 ± 5.90	59.87 ± 6.21	AA + CT	CT	4 t/d	VAS, HHS, AAS, AE
Usichenko et al. [33]	29/25	68 ± 10	66 ± 11	AA + CT	CT	3 d	VAS, AAS, AE

C: control group; *I*: intervention group; N/A: not applicable AA: auricular acupressure; CT: conventional treatment; VAS: visual analog scale; AAS: amount of analgesics used; HHS: Harris Hip Score; ER: effective rate; AE: adverse events.

2022. All of them were conducted in China and reported nonsignificant differences in their patient baseline characteristics. The main assessment tools were the VAS and the amount of analgesics used, HPS: Harris Hip Score, ER, and AE.

3.3. Methodological Quality Assessment. As shown in Figures 2 and 3, the risk of bias in the included studies was mainly derived from random sequence generation, allocation concealment, blinding of participants and personnel, and blinding of outcome assessment. Finally, 8 of the 14 RCTs were assessed as having a low overall risk of bias, and the rest had a high overall risk of bias.

3.4. Results of Meta-Analyses

3.4.1. Visual Analog Scale

(1) Visual Analog Scale at 12 h. VAS was used to score the pain degree of patients, which the score was in direct proportion to the pain degree. Eight trials with a total of 886 participants recorded VAS at 12 h of the intervention. The random effect model was applied, and pool results showed that AA could reduce VAS significantly in the experimental group than control group (MD -0.53, 95% CI -0.77 to -0.30) as shown in Figure 4. In addition, the data provided by the included studies were insufficient to support sub-group analyses, and therefore no further subgroup analyses were performed in subsequent analyses. The funnel plot was given in supplementary file B.

(2) Visual Analog Scale at 24 h. Eight trials with a total of 960 participants recorded VAS at 24 h of the intervention. The random effect model was applied, and pool results showed that AA could reduce VAS significantly in the experimental group than the control group (MD -0.59, 95% CI -0.92 to -0.25) as shown in Figure 5. Funnel plot was given in supplementary file B.

(3) Visual Analog Scale at 36 h. Three trials with a total of 532 participants recorded VAS at 36 h of the intervention. The fixed effect model was applied, and pool results showed that AA could reduce VAS significantly in experimental group than the control group (MD -0.07, 95% CI -0.13 to -0.02) as shown in Figure 6. Funnel plot was given in supplementary file B.

(4) Visual Analog Scale at 48 h. Nine trials with a total of 1002 participants recorded VAS at 48 h of the intervention. The random effect model was applied, and pool results showed that AA could reduce VAS significantly in the experimental group than control group (MD -0.52, 95% CI -0.97 to -0.08) as shown in Figure 7. The funnel plot was given in supplementary file B.

(5) Visual Analog Scale at 72 h. Six trials with a total of 826 participants recorded VAS at 72 h of the intervention. The random effect model was applied, pool results showed that AA could reduce VAS significantly in the experimental



FIGURE 2: Risk of bias summary.

group than control group (MD -0.72, 95% CI -1.02 to -0.42), as shown in Figure 8. The funnel plot was given in supplementary file B.

3.4.2. Harris Hip Score. Five trials with a total of 688 participants recorded HHS at the end of the intervention. The random effect model was applied and the pool results showed that AA could improve HHS significantly in the experimental group than control group (MD 6.58, 95% CI 3.60 to 9.56), as shown in Figure 9. The funnel plot was given in supplementary file B.

3.4.3. Amount of Analgesics Used. Five trials with a total of 682 participants recorded the amount of analgesics used at the end of the intervention. The random effects model was applied, and pool results showed that AA could reduce the amount of analgesics used significantly more in the experimental group than the control group (MD –12.35, 95% CI –14.21 to –10.48), as shown in Figure 10. The funnel plot was given in supplementary file B.



FIGURE 3: Risk of bias graph.

Study or Subgroup	Ex Mean	perimer SD	ntal Total	Mean	Contro SD	l Total	Weight (%)	Mean Difference IV, Random, 95% CI	Mean Difference IV, Random, 95% CI
Chen 2017	3.83	0.38	30	4.1	0.48	30	14.9	-0.27 [-0.49, -0.05]	
Lv 2017	3.22	0.45	49	3.76	0.46	49	15.6	-0.54 [-0.72, -0.36]	
Shen 2017	3.85	1.01	40	5.29	1.23	40	9.8	-1.44 [-1.93, -0.95]	
Tian 2016	3.27	1.14	36	3.83	1.52	36	7.9	-0.56 [-1.18, 0.06]	
Wang 2012	4.48	0.26	30	4.57	0.31	30	16.1	-0.09 [-0.23, 0.05]	
Wu 2019	6.41	0.87	29	7.26	0.58	31	11.9	-0.85 [-1.23, -0.47]	
Xu 2014	4.37	0.89	19	5.63	1.26	19	6.9	-1.26 [-1.95, -0.57]	
Zhu 2017	4.37	0.29	235	4.49	0.28	183	16.9	-0.12 [-0.17, -0.07]	
Total (95% CI)			468			418	100.0	-0.53 [-0.77, -0.30]	•
Heterogeneity: tau ² =	0.09; chi	$^{2} = 69.9$	9, df = 7	(P < 0.00)	001); <i>I</i> ²	r			
Test for overall effect	Z = 4.41	(<i>P</i> < 0.	0001)		-2	2 -1 0 1 2 Favours [experimental] Favours [control]			

FIGURE 4: Comparison of the VAS at 12 h between the AA group and the control group.

Study or Subgroup	Ex _] Mean	perimei SD	ntal Total	Mean	Contro SD	l Total	Weight (%)	Mean Difference IV, Random, 95% Cl	[N IV,	Mean Differ Random, 9	ence 5% CI	
Chen 2017	3.3	0.47	30	3.6	0.5	30	12.3	-0.30 [-0.55, -0.05]					
Li 2022	4.8	0.19	35	5.21	0.18	35	13.0	-0.41 [-0.50, -0.32]			-		
Lv 2017	3.47	0.55	49	3.98	0.53	49	12.5	-0.51 [-0.72, -0.30]			-		
Shen 2017	2.08	0.83	40	4.02	1.03	40	11.0	-1.94 [-2.35, -1.53]	←──				
Wang 2012	4.17	0.31	30	4.07	0.23	30	12.8	0.10 [-0.04, 0.24]					
Xu 2014	3.47	0.55	49	3.98	0.53	49	12.5	-0.51 [-0.72, -0.30]			-		
Xu 2021	2.59	0.33	38	3.79	0.1	38	12.9	-1.20 [-1.31, -1.09]					
Zhu 2017	3.88	0.28	235	3.98	0.18	183	13.1	-0.10 [-0.14, -0.06]			-		
Total (95% CI)			506			454	100.0	-0.59 [-0.92, -0.25]					
Heterogeneity: $tau^2 =$	0.23; chi	$^{2} = 443.$	54, df = 7	V(P < 0.00)	0001); I	$^{2} = 98\%$						1	
Test for overall effect	: Z = 3.40	P = 0.	0007)				-2	-1	0	1	2		
			<i>.</i>						Favor	ırs [experime	ntal]	Favours [cont	rol]

FIGURE 5: Comparison of the VAS at 24 h between the AA group and the control group.

3.4.4. Effective Rate. Two trials, with a total of 176 participants, recorded an effective rate at the end of the intervention. The fixed effect model was applied, and pool results showed that AA could increase the effective rate significantly in the experimental group than control group (OR 6.37, 95% CI 2.68 to 15.15), as shown in Figure 11. The funnel plot was given in supplementary file B. 3.4.5. Adverse Events. Four trials with a total of 232 participants recorded adverse events at the end of the intervention. The fixed effect model was applied, pool results showed that AA could reduce adverse events significantly in experimental group than control group (OR 0.35, 95% CI 0.17 to 0.71), as shown in Figure 12. Funnel plot was given in supplementary file B.



FIGURE 6: Comparison of the VAS at 36 h between the AA group and the control group.

Chu das on Cult moren	Ex	perimer	ntal		Contro	1	Weight	Mean Difference	Mean Difference
Study of Subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, Random, 95% CI	IV, Random, 95% CI
Chen 2017	3.1	0.31	30	3.33	0.48	30	11.3	-0.23 [-0.43, -0.03]	
Lv 2017	2.55	0.59	49	3.25	0.58	49	11.2	-0.70 [-0.93, -0.47]	
Tian 2016	2.51	0.72	36	2.87	0.95	36	10.6	-0.36 [-0.75, 0.03]	
Wang 2012	3.07	0.26	30	2.95	0.24	30	11.5	0.12 [-0.01, 0.25]	
Wu 2019	4	0.71	29	4.29	0.29	31	11.1	-0.29 [-0.57, -0.01]	
Xu 2014	1.89	0.66	19	2.37	0.89	19	10.1	-0.48 [-0.98, 0.02]	
Xu 2021	3.37	0.38	38	4.81	0.27	38	11.4	-1.44 [-1.59, -1.29]	
Yang 2018	5.4	0.7	60	6.8	0.5	60	11.3	-1.40 [-1.62, -1.18]	
Zhu 2017	3.21	0.28	235	3.12	0.19	183	11.6	0.09 [0.04, 0.14]	
Total (95% CI)			526			476	100.0	-0.52 [-0.97, -0.08]	
Heterogeneity: tau ² =	0.45; chi	$^{2} = 563.$	68, df = 8	P < 0.0	0001); 1	² = 99%		-2 -1 0 1 2	
Test for overall effect: $Z = 2.29 (P = 0.02)$									Favours [experimental] Favours [control]

FIGURE 7: Comparison of the VAS at 48 h between the AA group and the control group.

Charles and Carls and an	Ex	perimei	ntal		Contro	1	Weight	Mean Difference	Mean Difference				
Study or Subgroup	Mean SD		Total	Mean	SD	Total	(%)	IV, Random, 95% CI	IV, Random, 95% CI				
Chen 2017	2.3	0.47	30	2.5	0.51	30	15.8	-0.20 [-0.45, 0.05]					
Li 2022	2.67	0.14	35	3.16	0.21	35	17.5	-0.49 [-0.57, -0.41]	+				
Lv 2017	2.19	0.42	49	2.98	0.43	49	16.8	-0.79 [-0.96, -0.62]					
Wu 2019	3.1	0.49	29	3.52	0.57	31	15.5	-0.42 [-0.69, -0.15]					
Yang 2018	4	0.4	60	5.6	0.5	60	16.8	-1.60 [-1.76, -1.44]					
Zhu 2017	3.59	0.33	235	4.36	0.32	183	17.6	-0.77 [-0.83, -0.71]	• •				
Total (95% CI)			438			388	100.0	-0.72 [-1.02, -0.42]					
Heterogeneity: tau2 =	= 0.13; chi	$^{2} = 167.$	08, df = 5	6 (P < 0.0)	0001); i	$1^2 = 97\%$		г					
Test for overall effect	t: $Z = 4.74$	(<i>P</i> < 0.	00001)				-2	Favours [experimental] Favours [control]					

FIGURE 8: Comparison of the VAS at 72 h between the AA group and the control group.

Study or Subgroup	Experimental Mean SD Total			Mean	Control SD	l Total	Weight (%) I	Mean Difference IV, Random, 95% CI	Mean Difference IV, Random, 95% CI				
							. ,			-			
Chen 2017	80.07	11.05	30	78.97	11.44	30	14.2	1.10 [-4.59, 6.79]					
Li 2022	65.48	7.29	35	54.27	8.13	35	20.6	11.21 [7.59, 14.83]					
Wang 2012	78.9	5.1	30	73.4	6	30	23.4	5.50 [2.68, 8.32]					
Wang 2020	90.7	14.2	40	79.4	13.9	40	13.1	11.30 [5.14, 17.46]					<u> </u>
Zhu 2017	77.5	4.8	235	72.8	5.8	183	28.6	4.70 [3.66, 5.74]					
Total (95% CI)			370			318	100.0	6.58 [3.60, 9.56]					
Heterogeneity: tau2 =	= 7.81; chi	$^{2} = 17.2$	8, $df = 4$	(P = 0.00)	2); $I^2 = 2$	77%							
Test for overall effect	t: $Z = 4.33$	P < 0.	0001)						-10	-5	0	5	10
			,						Favours [ex	periment	al]	Favour	rs [control]

FIGURE 9: Comparison of the HHS between the AA group and the control group.

3.5. *Evidence Quality Assessment*. Due to limitations of the enrolled trails, the strength of the evidence was weakened for all outcomes. Inconsistency, imprecision, and publication bias also limited the strength of the evidence for some outcomes.

Finally, one of the outcomes was assessed as low moderate quality, and the rest were of low or very low quality. Funnel graphs for these outcomes are given in Appendix B. Details are outlined in Table 2.

Ct., 1.,	Exp	perimer	ntal		Contro	1	Weight	Mean Difference		Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	(%)	IV, Random, 95% CI		IV, Rando	m, 95% CI			
Li 2022	52.54	1.96	35	63.42	2.68	35	29.3	-10.88 [-11.98, -9.78]						
Shen 2017	52.6	1.9	40	63.5	2.6	40	29.8	-10.90 [-11.90, -9.90]						
Usichenko 2005	46	22	29	67	31	25	1.6	-21.00 [-35.55, -6.45]+						
Wang 2012	60.4	8.2	30	73.9	8.3	30	12.4	-13.50 [-17.68, -9.32]						
Zhu 2017	59.6	7.6	235	74.1	7.8	183	27.0	-14.50 [-15.99, -13.01]						
Total (95% CI)			369			313	100.0	-12.35 [-14.21, -10.48]	•					
Heterogeneity: tau2 =	2.79; chi	$^{2} = 20.4$	4, df = 4 (P = 0.00	$(04); I^2 =$	80%					1	1		
Test for overall effect	: Z = 12.9	5(P < 0)	0.00001)					-20	-10		0	10	20	
									Favours [expe	erimental]	Favours	[control]		

FIGURE 10: Comparison of the amount of analgesics used between the AA group and the control group.

Study or Subgroup	Experir	nental	Con	itrol	Weight	Odds Ratio		Odds Ratio				
Study of Subgroup	Events	Total	Events	Total	(%)	M-H, Fixed, 95% Cl	[M-H, Fixe	d, 95% CI			
Sun 2020	45	48	39	48	50.4	3.46 [0.88, 13.69]		-				
Yang 2018	56	60	36	60	49.6	9.33 [2.99, 29.13]						
Total (95% CI)		108		108	100.0	6.37 [2.68, 15.15]						
Total events	101		75									
Heterogeneity: chi ² = 1 Test for overall effect: .	1.19, df = 1 (Z = 4.19 (P <	P = 0.28); < 0.001)	$I^2 = 16\%$				0.01 Fa	0.1 1 vours [experimental]	10 Favours [control]	100		





FIGURE 12: Comparison of the adverse events between the AA group and the control group.

4. Discussion

In recent years, there have been more publications on AA for postoperative pain among patients with HF. However, interpretation of this evidence from these studies is difficult. We conducted this study to systematically evaluate the clinical effect of AA on postoperative pain in HF patients.

4.1. Summary of Main Results. In this study, 14 trails involving 1390 patients were included for meta-analysis. First, the pooled results suggested that AA combined with CT was significantly superior to CT alone in terms of VAS at 12, 24, 48, 36 h, and 72 h, HHS, amount of analgesics used, ER, and AE. These results indicated that AA can help reduce post-operative pain degree, reduce the amount of analgesics, improve hip function, and reduce the incidence of AE among HF patients. Second, it should be emphasized that methodological flaws are prevalent in existing RCTs. Most RCTs did not report proper allocation concealment or blinding procedures for outcome assessments. Furthermore,

no study was blinded to participants and personnel, suggesting potential performance bias. Of the 7 bias items, only one study met the requirement for low risk of bias. Third, the evidence quality was generally evaluated as "moderate" "low" or "very low" by the GRADE system. No study was rated as having a high level of evidence. Although AA has been widely used in China, and the pooled analysis of this study has yielded that AA combined with CT was likely to have potential therapeutic benefits in postoperative pain among HF patients, but the level of evidence was not high. There may still be gaps between the evidence supporting the efficacy of AA and its clinical implementation. Further trials with rigorous methodology, including standard protocols for AA and multiethnic subjects, are still warranted to provide stronger evidence. Fourth, limited by insufficient data, this study was unable to evaluate the long-term effects of AA. The included studies only evaluated the use of AA for several days and assessed outcomes before and immediately after treatment, therefore, the long-term effects of AA on postoperative pain could not be revealed.

					TABLE 2: Lev	vel of evidence.			
				Certainty asse	essment			Man differences	Certainty of
Outcoi	nes	No of participants (studies)	Limitations	Inconsistency	Indirectness	Imprecision	Publication bias	(95% CI)	the evidence (GRADE)
	12 h	886 (8)	Serious ^①	Serious®	No	No	Serious [@]	MD-0.53, 95% CI -0.77 to -0.30	⊕⊕⊖⊖⊖ very low
	24 h	960 (8)	Serious [©]	Serious®	No	No	Serious [®]	MD-0.59, 95% CI -0.92 to -0.25	⊕⊕⊖⊖⊖ very low
VAS	36 h	532 (3)	Serious ^①	No	No	No	No	MD -0.07, 95% CI -0.13 to -0.02	⊕⊕⊕⊕⊖ Moderate
	48 h	9 (1002)	Serious ^①	Serious®	No	No	Serious [@]	MD -0.52, 95% CI -0.97 to -0.08	⊕⊕⊖⊖⊖ very low
	72 h	6 (826)	Serious [©]	Serious®	No	No	Serious [®]	MD -0.72, 95% CI -1.02 to -0.42	⊕⊕Ó⊖⊖ very low
AAS		4 (682)	Serious ^①	Serious [®]	No	No	Serious [®]	MD -12.35, 95% CI-14.21 to -10.48	⊕⊕⊖⊖⊖ very low
SHH		5 (688)	Serious ^①	Serious [®]	No	No	Serious [®]	MD 6.58, 95% CI 3.60 to 9.56	⊕⊕⊖⊖⊖ Very low
ER		2 (176)	Serious ^①	No	No	Serious [®]	Serious [®]	OR 6.37, 95% CI 2.68 to 15.15	⊕⊕⊕⊖⊖ Low
AE		4 (232)	Serious ^①	No	No	No	Serious [®]	OR 0.35, 95% CI 0.17 to 0.71	⊕⊕⊕⊖⊖ Low
OR: odd random, the simp	s ratio; M distribut de size w	ID: MD: mean difference; VA ive findings or was blinded; ^{\mathfrak{G}} as small; ^{\mathfrak{G}} funnel graph asy	S: visual analog sc ⁹ the confidence in mmetry.	ale; AAS: amount of terval overlapped less	analgesics used; HI s, the <i>P</i> value of the	HS: Harris Hip Scc heterogeneity test	ıre; ER: effective rate; A) was very small, and the	E: adverse events: [©] the experimental design hac I^2 was larger; [©] the confidence interval was not n	l a large bias in its iarrow enough, or

4.2. Agreements and Disagreements with Other Studies or Reviews. This review agrees with the results of the other study [34] in the aspect that AA as a complement to conventional drugs reduces postoperative pain, though with uncertainty. A systematic review [34] reported that in postoperative patients with fractures treated with AA, the degree of pain significantly improved 24 hours after surgery and was also significantly lower than in the control group in terms of ER. These results agree with our study. However, this review [34] focused only on pain at one time point and did not address the question of duration of action, and this study included patients with all types of fractures. The difference in our review is that we focused on patients with HF and observed pain at multiple time points after surgery and also on HHS, amount of analgesics used, and AE, making the assessment more comprehensive. In addition, as in the previous review, this study was also limited by the high risk of bias in the included trials, so the level of evidence obtained was not high. More welldesigned, rigorous, and large trials are needed in this field.

4.3. Implications for Practice. In addition to shorter hospital stays and reduced morbidity and mortality, effective relief of acute postoperative pain is associated with increased patient satisfaction [33]. AA is an ancient Chinese non-pharmacological treatment that has been reported to be effective and safe in improving multiple factors in fracture patients and has the potential to promote postoperative recovery in combination with CT. Although the current review did not provide the best evidence, the results suggested that the combination of AA with CT postoperative pain degree, reduce the amount of analgesics, improve hip function, and reduce the incidence of AE among HF patients.

AA has been used to treat various types of pain, including postoperative, musculoskeletal pain, and pain associated with anesthesia [35]. The analgesic effect of AA has been preliminarily revealed. Research studies have found that AA stimulation can activate the descending pain inhibitory pathway in the brainstem-spinal cord and inhibit the ascending pain pathway, which in turn exerts analgesic effects [36]. It has been found that acupoint stimulation of one or both ears can increase the pain threshold [37], and this effect peaks 5–10 minutes after stimulation and lasts for hours to days [38]. Furthermore, it has been suggested that the analgesic effect of AA is also associated with the endogenous opioid system [39].

4.4. Limitations. Considering that all included trails were conducted in China, it should be noted that publication bias was also observed in this meta-analysis, which indicates that the results of this review may be challenging to generalize, especially in countries other than China. As a country that has practiced AA for a long time, Chinese attitudes towards AA may be more favorable than those of other ethnic groups, which may contribute to the placebo effect. Therefore, further studies in countries other than China are still needed. Furthermore, the diversity of the AA protocol used in the included trails may contribute to the

heterogeneity of the findings [40]. While complementary and alternative therapies, such as AA, may emphasize tailoring treatments to individual patient characteristics, developing basic treatment standards that allow for some modifications can improve the quality of clinical evidence in this field.

5. Conclusion

Compared with CT alone, the combination of AA and CRT had a significantly greater effect on postoperative pain in HF patients. However, trails with a rigorous methodology, including standard protocols for AA and multiethnic subjects, are still needed.

Abbreviations

AA:	Auricular acupressure
HF:	Hip fracture
N/A:	Not applicable
AA:	Auricular acupressure
CT:	Conventional treatment
VAS:	Visual analog scale
AAS:	Amount of analgesics used
HHS:	Harris Hip Score
ER:	Effective rate
AE:	Adverse events
GRADE:	Grading of recommendations, assessment,
	development, and evaluation
RCTs:	Randomized clinical trials
PRISMA:	Preferred reporting items for systematic reviews
	and meta-analyses
OR:	Odds ratio
SMD:	Standardized mean difference.

Data Availability

The detailed search strategy is given in Appendix A. All analyses were based on previously published studies.

Conflicts of Interest

The authors declare that they have no conflicts of interest in the publication of this study.

Authors' Contributions

Xiaohi Qin and Pin Li designed the study and drafted the manuscript. Xiuzhen Fu, Haili Zhou, and Fan Lai contributed to the literature search, figures, data collection, and data analysis. Hongyun Chen provided guidance on the methodology. All authors have read and approved the final manuscript.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (no. 81974574).

Supplementary Materials

The detailed search strategy for the PubMed is given in supplementary file A. Funnel plot for outcomes was given in supplementary file B. (*Supplementary Materials*)

References

- L. Partridge, J. Deelen, and P. E. Slagboom, "Facing up to the global challenges of ageing," *Nature*, vol. 561, no. 7721, pp. 45–56, 2018.
- [2] W. H. Organization, World Health Statistics 2021: Monitoring Health for the SDGs, Sustainable Development Goals, World Health Organization, Geneva, Switzerland, 2021.
- [3] M. Sander, B. Oxlund, A. Jespersen et al., "The challenges of human population ageing," *Age and Ageing*, vol. 44, no. 2, pp. 185–187, 2015.
- [4] C. Cooper, G. Campion, and L. J. Melton III, "Hip fractures in the elderly: a world-wide projection," Osteoporosis International, vol. 2, no. 6, pp. 285–289, 1992.
- [5] C. Cooper, Z. A. Cole, C. R. Holroyd et al., "Secular trends in the incidence of hip and other osteoporotic fractures," *Osteoporosis International*, vol. 22, no. 5, pp. 1277–1288, 2011.
- [6] H. Y. Wan, S. Y. Li, W. Ji, B. Yu, and N. Jiang, "Fascia iliaca compartment block for perioperative pain management of geriatric patients with hip fractures: a systematic review of randomized controlled trials," *Pain Research and Management*, vol. 2020, Article ID 8503963, 12 pages, 2020.
- [7] M. Bhandari and M. Swiontkowski, "Management of acute hip fracture," *New England Journal of Medicine*, vol. 377, no. 21, pp. 2053–2062, 2017.
- [8] American Academy of Orthopedic Surgeons, "Management of hip fractures in the elderly: guidelines," 2014, https://www. aaos.org/CustomTemplates/Content.aspx?id=6395&ssopc=1.
- [9] K. S. Feldt, M. B. Ryden, and S. Miles, "Treatment of pain in cognitively impaired compared with cognitively intact older patients with hip-fracture," *Journal of the American Geriatrics Society*, vol. 46, no. 9, pp. 1079–1085, 1998.
- [10] R. Cowan, J. H. Lim, T. Ong, A. Kumar, and O. Sahota, "The challenges of anaesthesia and pain relief in hip fracture care," *Drugs & Aging*, vol. 34, no. 1, pp. 1–11, 2017.
- [11] O. Sahota, M. Rowlands, J. Bradley et al., "Femoral nerve block intervention in neck of femur fracture (FINOF): study protocol for a randomized controlled trial," *Trials*, vol. 15, no. 1, p. 189, 2014.
- [12] C. Grey and P. B. Hall, "Considerations of prescription opioid abuse and misuse among older adults in West Virginia—an under-recognized population at risk," *West Virginia Medical Journal*, vol. 112, no. 3, pp. 42–47, 2016.
- [13] B. Y. Liu, B. Chen, Y. Guo, and L. X. Tian, "Acupuncturea national heritage of China to the world: international clinical research advances from the past decade," *Acupuncture and Herbal Medicine*, vol. 1, no. 2, pp. 65–73, 2021.
- [14] Y. Guo, Y. M. Li, T. L. Xu et al., "An inspiration to the studies on mechanisms of acupuncture and moxibustion action derived from 2021 Nobel Prize in Physiology or Medicine," *Acupuncture and Herbal Medicine*, vol. 2, no. 1, pp. 1–8, 2022.
- [15] Acupuncture, "NIH consens statement," 1997, https:// journals.sagepub.com/doi/pdf/10.1177/153321019900500211.
- [16] J. Higgins, S. Green, and C. Collaboration, Cochrane Handbook for Systematic Reviews for Interventions. Cochrane Database of Systematic Reviews, The Cochrane Collaboration, Bristol, UK, 2011.

- [17] D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and Prisma Group, "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement," *PLoS Medicine*, vol. 6, no. 7, Article ID e1000097, 2009.
- [18] J. Huang, J. Liu, Z. Liu et al., "Reliability of the evidence to guide decision-making in acupuncture for functional dyspepsia," *Frontiers in Public Health*, vol. 10, Article ID 842096, 2022.
- [19] A. Pollock, S. E. Farmer, M. C. Brady et al., "An algorithm was developed to assign GRADE levels of evidence to comparisons within systematic reviews," *Journal of Clinical Epidemiology*, vol. 70, pp. 106–110, 2016.
- [20] H. L. Li, H. Xu, W. Zhang et al., "Application of auricular acupoint compression in perioperative analgesia of femoral head replacement in elderly patients with femoral neck fracture," *World Journal of Integrated Traditional and Western Medicine*, vol. 17, no. 4, pp. 796–801, 2022.
- [21] U. Xu and S. Li, "Application of auricular acupoint pressing in relieving post operative pain of senile hip fracture," *Chinese Medicine Modern Distance Education of China*, vol. 19, no. 1, pp. 140–142, 2021.
- [22] X. Sun, "Observation on the curative effect of ear point embedding beans in the treatment of perioperative pain in patients with femoral neck fracture," *Home Medicine*, no. 11, p. 361, 2020.
- [23] X. Wu and Q. Wang, "Interventional study of auricular point magnetic therapy on pain perception in patients after total hip arthroplasty," *Gansu Medical Journal*, vol. 38, no. 5, pp. 437-438, 2019.
- [24] L. Wang, X. Pan, and W. Xie, "Nursing experience of auricular point pressing bean for patients with pain after hip joint replacement," *Journal of Medical Aesthetics and Cosmetology*, vol. 27, no. 8, p. 81, 2018.
- [25] L. Yang, "Effect of auricular point pressing bean on postoperative pain care of patients with femoral fracture," *China Practical Medicine*, vol. 13, no. 19, pp. 159–161, 2018.
- [26] Q. Chen, Clinical Effect of Auricular point Pressing Pill on Perioperative Analgesia of Intertrochanteric Fractures in the Elderly, Fujian University of Chinese Medicine, Fujian, China, 2017.
- [27] M. Lv, "Observation on 49 cases of auricular point buried beans relieving pain after hip arthroplasty," *Zhejiang Journal* of Traditional Chinese Medicine, vol. 52, no. 7, p. 504, 2017.
- [28] Z. Zhu, "Study on the effect of auricular point needle embedding on VAS Score and hip joint function in patients undergoing perioperative total hip replacement," *China Modern Doctor*, vol. 55, no. 13, pp. 125–128, 2017.
- [29] F. Shen and M. Zhou, "Effect of ear pressure on postoperative analgesia and patient-controlled analgesia in elderly patients after total hip replacement," *Jiangsu Journal of Traditional Chinese Medicine*, vol. 49, no. 9, pp. 61-62, 2017.
- [30] J. Tian, P. Ding, and K. Zhai, "The therapeutic effect observation of auricular acupoint pressing in relieveing pain after total hip replacement," *Clinical Journal of Traditional Chinese Medicine*, vol. 28, no. 1, pp. 127–129, 2016.
- [31] B. Xu, "Application of preemptive analgesia with auricular point combined with selexib in total hip arthroplasty," *Journal* of Emergency in Traditional Chinese Medicine, vol. 23, no. 4, pp. 766-767, 2014.
- [32] J. Wang, H. Bao, Y. Cai, J. Zhang, and P. Tong, "Case-control study on application of auricular acupuncture for the treatment of analgesia during perioperative period in total hip arthroplasty," *China Journal of Orthopaedics and Traumatology*, vol. 25, no. 3, pp. 220–223, 2012.

- [33] T. I. Usichenko, M. Dinse, M. Hermsen, T. Witstruck, D. Pavlovic, and C. Lehmann, "Auricular acupuncture for pain relief after total hip arthroplasty - a randomized controlled study," *Pain*, vol. 114, no. 3, pp. 320–327, 2005.
- [34] Y. Q. Zhang, X. Sun, Y. Zong, J. Y. Cao, and X. Y. Zhou, "Meta-analysis of auricular point sticking therapy for postoperative pain after fracture surgery," *Clinical Journal of Traditional Chinese Medicine*, vol. 31, no. 10, pp. 1867–1871, 2019.
- [35] C. H. Yeh, Y. C. Chiang, S. L. Hoffman et al., "Efficacy of auricular therapy for pain management: a systematic review and meta-analysis," *Evidence-based Complementary and Alternative Medicine*, vol. 201414 pages, Article ID 934670, 2014.
- [36] T. Oleson, "Neurophysiological basis of auricular acupuncture," in *Clinical Acupuncture*, G. Stux and R. Hammerschlag, Eds., Springer, Berlin, Germany, 2001.
- [37] A. W. Krause, J. A. Clelland, C. J. Knowles, and J. R. Jackson, "Effects of unilateral and bilateral auricular transcutaneous electrical nerve stimulation on cutaneous pain threshold," *Physical Therapy*, vol. 67, no. 4, pp. 507–511, 1987.
- [38] L. B. Noling, J. A. Clelland, J. R. Jackson, and C. J. Knowles, "Effect of transcutaneous electrical nerve stimulation at auricular points on experimental cutaneous pain threshold," *Physical Therapy*, vol. 68, no. 3, pp. 328–332, 1988.
- [39] M. S. Simmons and T. D. Oleson, "Auricular electrical stimulation and dental pain threshold," *Anesthesia Progress*, vol. 40, no. 1, pp. 14–19, 1993.
- [40] J. Huang, M. Shen, X. Qin, and Y. Huang, "Effectiveness of auricular acupuncture for insomnia: an overview of systematic reviews," *Evidence-based Complementary and Alternative Medicine*, vol. 2020, Article ID 6920902, 6 pages, 2020.